Summary of the Rights Issue
On 10 December 2018 the Board of Directors resolved, subject to approval by general meeting, to increase the Company’s share capital by an issue of shares with preferential rights for existing shareholders. The Board of Directors resolution was approved by the extraordinary general meeting on 17 January 2019. The Company’s shareholders have preferential rights to subscribe for new shares in relation to the number of shares they owned on the record date of 21 January 2019 at a subscription price of SEK 1.35 per share. The Rights Issue entitles the holder of one (1) existing share in Company to one (1) subscription right. One (1) subscription right entitles to subscription of one (1) newly issued share. On full subscription of the Rights Issue, the Company will raise approximately SEK 123.8 million before issue costs.
Schedule for the Rights Issue in brief (all dates refer to 2019)
Wednesday 23 January Subscription period starts
Wednesday 23 January Trading in subscription rights starts
Monday 4 February Trading in subscription rights ends
Wednesday 6 February Subscription period ends
Monday 11 February Announcement of outcome of Rights Issue
NeuroVive has appointed Stockholm Corporate Finance AB as financial advisor, Cirio Advokatbyrå AB as legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing agentin connection with the Rights Issue.
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 22 January 2019.
For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, 223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
Publication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and persons in jurisdictions where this press release has been made public or distributed should inform themselves and follow such legal restrictions. This press release does not contain and does not constitute an invitation or an offer to acquire, subscribe or otherwise trade in shares or other securities in NeuroVive.
This press release may not be published, distributed or made public, directly or indirectly, in or into the US, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa, Switzerland or in any other jurisdiction where such action, completely or partially, is subject to legal restrictions. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 or applicable laws of other jurisdictions.